NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading BLFS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a speculative growth investment. The company is working on increasing revenue and improving profitability, but it is currently not profitable and has a mixed record on margin expansion.
The market seems to have priced in a justified valuation, reflecting a low expectations gap. However, it trades at a premium compared to peers, indicating that investors are factoring in some potential for future growth.
Management has set clear priorities to increase revenue and enhance net income, with recent results showing strong revenue growth. However, gross margin has slightly declined, and while there is a low probability of missing guidance, the company has a history of volatility.
The long-term thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX, which could influence BLFS's growth. Additionally, any changes in guidance from management could significantly impact investor sentiment.
Overall, BLFS is navigating a complex landscape with strong recent performance but faces challenges due to its loss-making status. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: If revenue growth is below this level, it may show less demand for cell therapy.
Confirms:Q2 revenue growth was below 17% compared to last year.
Disproves:Q2 revenue growth reported at or above 17% year-over-year.
Why it matters: The acquisition will help BioLife reach more customers and offer more products. It may increase revenue and profits.
Confirms:The acquisition will close by the end of Q4 2026. All regulatory approvals are secured.
Disproves:The acquisition may face delays. It could also fail to get the needed regulatory approvals.
Why it matters: This will show if BioLife keeps growing and meets its goals.
Confirms:Q2 2026 revenue must be at or above $28.5 million. This confirms 21% growth from last year.
Disproves:Q2 2026 revenue is below $28.5 million. This shows growth is slowing.
Why it matters: Higher operating income means better cost control. It shows the company is more efficient.
Confirms:Operating income was over $0.5 million in Q2 2026.
Disproves:Operating income was below $0 in Q2 2026.
Why it matters: New product approvals could drive future revenue growth and market share.
Confirms:At least one new product approval or a big partnership is announced.
Disproves:No news on new product approvals or partnerships.
Why it matters: A decline means less profit and may hurt investor confidence.
Confirms:Net income reported lower than $1.2 million in Q2 2026.
Disproves:Net income reported at or above $1.2 million in Q2 2026.
Why it matters: If it drops below this level, it shows problems with costs and pricing.
Confirms:Gross margin is expected to be below 60% in the next earnings report.
Disproves:Gross margin remains at or above 60%.
Why it matters: Gross margin trends will show if BioLife can keep making money while growing.
Confirms one read:Gross margin reported at or above 64% in Q2 2026.
Confirms the other:Gross margin reported below 64% in Q2 2026.
